Clinical Trial Update: A Study Evaluating the Safety and Efficacy of ENV-101 in Subjects With Idiopathic Pulmonary Fibrosis (IPF) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ENV-101 for idiopathic pulmonary fibrosis has completed, with an update on safety and efficacy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Pulmonary Fibrosis

Drugs mentioned

• ENV-101

Snippet

Sponsor: Endeavor Biomedicines, Inc. | Conditions: Idiopathic Pulmonary Fibrosis | Phase 2 | Status: COMPLETED